By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic . The royalty deal extends uniQure’s cash runway into 2026.
AstraZeneca is jumping into the chase for cell therapies that address solid tumors by acquiring Neogene Therapeutics. The startup’s technology can be used to discover and develop novel targets that may be able to broaden the scope of cell therapies for cancer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Targeting mutations isn’t the only way to treat genetically driven diseases. Scenic Biotech is developing molecules to target genes that suppress disease, and it has raised $31 million to advance its pipeline of potential therapies for cancer and rare diseases.
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.
A uniQure gene therapy for hemophilia B that has been under a clinical hold for four months can now resume testing. The hold was lifted after uniQure answered the FDA's questions about whether the gene therapy caused the liver cancer diagnosed in one patient who received the therapy.
UniQure is making a case for lifting a clinical hold on its hemophilia B gene therapy, reporting Monday results of an independent investigation that appear to clear the experimental treatment as the cause of a patient’s cancer.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Founded by scientists behind the technology used in Johnson & Johnson's Covid-19 vaccine, Leyden Laboratories is developing intranasal medicines intended to stop viruses before they infect the lungs. SARs-CoV-2 is one target, but the startup plans to address many respiratory pathogens.
The therapy, etranacogene dezaparvovec, is currently in Phase III clinical development for hemophilia B. Shares of uniQure were down nearly 20%, but an investment bank analyst wrote that the financial terms were favorable for the company.
The company presented updated data for the drug, voxelotor, at the European Hematology Association conference in Amsterdam Friday.
On Saturday, the company will present a poster of Phase I trial data for belantamab mafodotin, which targets the same antigen, BCMA, as Amgen bispecific antibody AMG 420 and multiple CAR-T cell therapies in development.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Financial Times reported Monday that the Japanese drugmaker would merge its UK operations with a Dutch subsidiary.
Many supporters of the UK's withdrawal from the EU say "no deal, no problem," but drugmakers' actions suggest "no deal, big problem."
The Fitch Solutions report, released this week, notes that the number of clinical trials taking place in the UK has already fallen more than 25 percent.
European Medicines Agency faces greater loss of staff than anticipated, forcing it to scale back or suspend some activities.
Philips will help Omaha, Nebraska-based Children's Hospital & Medical Center with its technology innovation. The collaboration will focus on various areas, including diagnostic imaging, patient monitoring, clinical informatics and respiratory solutions.